Publication | Closed Access

Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy

Cell-based Drug DeliveryNanomedicineDrug TargetingNanotherapeuticsPolymer-drug ConjugateMedicineImmunologyTumor ImmunityAnti-cancer EfficacyTumor TargetingAnti-cancer AgentSialic Acid-modified LiposomesImmunotherapyPharmacologyChlorogenic AcidTumor Microenvironment